Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to t
MSD's PD-1 inhibitor Keytruda has ruled the immunotherapy of non-small cell lung cancer (NSCLC) for many years, but a bispecific antibody from Summit Therapeutics and partner Akeso looks li
MSD and Daiichi Sankyo have revealed some of the clinical data that prompted them to start pivotal testing of ifinatamab deruxtecan (I-DXd) in patients with previously treated, extensive-st